« Förderinformationen
Sie verwenden einen sehr veralteten Browser und können Funktionen dieser Seite nur sehr eingeschränkt nutzen. Bitte aktualisieren Sie Ihren Browser. http://www.browser-update.org/de/update.html
Gene and Cell Based Therapies to Counteract Neuroretinal Degeneration
Deutsche Forschungsgemeinschaft (DFG)
The Senate of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has established a new Priority Programme entitled ,,Gene and Cell Based Therapies to Counteract Neuroretinal Degeneration" (SPP 2127). The programme is designed to run for six years. The present call invites proposals for the first three-year funding period.
Gene and cell based therapies take centre stage in the attempt to find effective ways to treat rare diseases. Vision loss due to inherited retinal dystrophies is a severe burden for two to four million patients worldwide and innovative strategies defeating neuronal dysfunction and cell loss are urgently needed. While the current state of the art is quite advanced in the field of experimental therapies of inherited retinal dystrophies, with clinical trials ongoing for some disorders and functional rescue to a certain level evident, the results of the current trials and preclinical experimentations as well as the improved understanding of the pathology of many inherited retinal dystrophies require continued work at high level. The major points arising in this striving field can be allocated to four main topics that are closely related and intercalate with each other.

Applications for the first three-year funding period should be written in English and submitted by 30 August 2017 via the electronic elan system.

Contact Person:
Prof. Dr. Dr. Knut Stieger, Justus-Liebig-University Gießen, phone +49 641 985-43835, knut.stieger@uniklinikum-giessen.de
Dr. Anna Christa, DFG, phone +49 228 885-2632, anna.christa@dfg.de

Weitere Informationen: